Navigation Links
Randomized Clinical Trial of OrbusNeich's Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
Date:10/11/2010

HONG KONG, Oct. 11 /PRNewswire/ -- OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China.

The primary objective of the 180 patient, controlled study is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor® Sprint stent in patients with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months after implantation and 270 day angiographic Late Loss (LL). Patients enrolled in the study were split evenly between the control and test arms.

"Based on its unique design and healing technology, we believe that Genous has the potential to give physicians an additional option for treating patients," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial. "We are excited to complete enrollment in this study, which may bring further clinical support for the technology's use in China."

David Chien, vice chairman of OrbusNeich, added, "This first clinical study of Genous in China is significant in the full development of the technology. We look forward to seeing additional clinical support for the use of Genous in challenging cases, such as diabetic patients and those who cannot tolerate a year of dual antiplatelet therapy."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
2. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
3. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
4. Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
5. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
6. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
7. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
10. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Ill. , Aug. 3, 2015 Your ... problem, and you,re looking for the best possible outcome. ... the best outcome too, and now there,s a ... Following steps recommended by the American Orthopaedic Foot ... surgery can help you avoid complications and heal as ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2
... 22 Dynavax,Technologies Corporation (Nasdaq: DVAX ) today ... ragweed allergy therapy, to subjects as,part of an environmental ... of 300 subjects. Subjects are being screened based on ... Exposure to ragweed allergen in,the chamber is being used ...
... 22 Boston,Scientific Corporation (NYSE: BSX ) ... which continue to support the proven safety and,efficacy ... and add to the growing body of strong ... Coronary,Stent System. An analysis of the data was ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 2Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 4
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 miles from ... California’s northernmost and among its least visited State Parks. The volcanic area beneath ... outflow is at Ahjumawi Lava Springs, part of the Fall River Springs complex. ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... AZ (PRWEB) , ... August 03, 2015 , ... Dignity ... Dignity Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The ... earlier this year in the West Valley. , “Dr. Baldwin is an excellent ...
(Date:8/3/2015)... ... 2015 , ... Cambia Health Solutions has promoted Scott Powers ... Medicare and Federal Employee Programs (FEP) lines of business. , Government programs ... In this role, Scott is responsible for overseeing the growth, finance and operations ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... being held from May 19-20, 2008 at the Le,Meridien ... Chief Executive Officer, will provide an overview of the,company ... in the Zephyr Salon., To access a simultaneous ...
... Foundation to celebrate,scientific advancements that have fueled longer life ... To celebrate,remarkable progress in treating cystic fibrosis -- ... the Cystic Fibrosis Foundation,to join the company as honored ... Life expectancy for people with CF has more than ...
... Company Prepares for, Potential 2008 Launch of MOXATAG; Keflex Product Sales ... ... in Quarter, GERMANTOWN, Md., May 13 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... anti-infective products, today,announced financial and operational results for the quarter ended ...
... impact EPA,s clean air regulations, researchers say , , TUESDAY, ... particles, such as those found in windblown dust or ... not appear to be linked to hospital admissions, a ... for short, is between 2.5 and 10 micrometers or ...
... studies report, , , TUESDAY, May 13 (HealthDay News) -- New ... breast cancer risk. , The bad news is a ... with breast cancer face an increased risk of breast cancer ... according to a study in the May 13 issue of ...
... used to treat a rare but well-known genetic disorder may ... with potentially lethal enlarged hearts, due mainly to high blood ... The common denominator in both phenylketonuria (PKU) and cardiac hypertrophy ... coworker helps break down the molecule phenylalanine whose buildup is ...
Cached Medicine News:Health News:Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th 2Health News:Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 13Health News:No Link Between Coarse Air Pollution, Hospitalizations 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Drug therapy for PKU reverses heart damage 2Health News:Drug therapy for PKU reverses heart damage 3Health News:Drug therapy for PKU reverses heart damage 4
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... Family offers fast temperature control, exact block ... Personal cards enable safe program storage as ... individual protocols between different Mastercyclers. All models ... come with a two-year warranty. The ...
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... graphical touch screen display which enables you ... of a screen." Features & Benefits ... Graphical Display, Memory Cards, Gradient Calculator, Fold ... Programmin, Free Instrument Software Upgrade. Includes ...
Medicine Products: